223 related articles for article (PubMed ID: 15837765)
1. Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer.
Akada M; Crnogorac-Jurcevic T; Lattimore S; Mahon P; Lopes R; Sunamura M; Matsuno S; Lemoine NR
Clin Cancer Res; 2005 Apr; 11(8):3094-101. PubMed ID: 15837765
[TBL] [Abstract][Full Text] [Related]
2. Elucidation of the relationship of BNIP3 expression to gemcitabine chemosensitivity and prognosis.
Ishida M; Sunamura M; Furukawa T; Akada M; Fujimura H; Shibuya E; Egawa S; Unno M; Horii A
World J Gastroenterol; 2007 Sep; 13(34):4593-7. PubMed ID: 17729412
[TBL] [Abstract][Full Text] [Related]
3. Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis.
Erkan M; Kleeff J; Esposito I; Giese T; Ketterer K; Büchler MW; Giese NA; Friess H
Oncogene; 2005 Jun; 24(27):4421-32. PubMed ID: 15856026
[TBL] [Abstract][Full Text] [Related]
4. Identifying molecular markers for chemosensitivity to gemcitabine in pancreatic cancer: increased expression of interferon-stimulated gene 15 kd is associated with intrinsic chemoresistance.
Ina S; Hirono S; Noda T; Yamaue H
Pancreas; 2010 May; 39(4):473-85. PubMed ID: 19959962
[TBL] [Abstract][Full Text] [Related]
5. Array analysis for potential biomarker of gemcitabine identification in non-small cell lung cancer cell lines.
Zhang HH; Zhang ZY; Che CL; Mei YF; Shi YZ
Int J Clin Exp Pathol; 2013; 6(9):1734-46. PubMed ID: 24040438
[TBL] [Abstract][Full Text] [Related]
6. Identifying genes with differential expression in gemcitabine-resistant pancreatic cancer cells using comprehensive transcriptome analysis.
Nakai Y; Otsuka M; Hoshida Y; Tada M; Komatsu Y; Kawabe T; Omata M
Oncol Rep; 2005 Nov; 14(5):1263-7. PubMed ID: 16211294
[TBL] [Abstract][Full Text] [Related]
7. [Mechanisms of the drug resistance of a 2', 2-difluorodeoxycytide (gemcitabine)-resistant variant of the human lung adenocarcinoma cell line].
Dong M; Feng FY; Lin C; Zhang XY; Fu M; Liang X; Zha YY; Lu HY; Wu M
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):323-8. PubMed ID: 15059518
[TBL] [Abstract][Full Text] [Related]
8. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
9. Mechanism Comparison of Gemcitabine and Dasatinib-Resistant Pancreatic Cancer by Integrating mRNA and miRNA Expression Profiles.
Chen Z; Zhao L; Shi K; Chen B
Clin Lab; 2018 May; 64(5):749-757. PubMed ID: 29739052
[TBL] [Abstract][Full Text] [Related]
10. S100A4 contributes to the suppression of BNIP3 expression, chemoresistance, and inhibition of apoptosis in pancreatic cancer.
Mahon PC; Baril P; Bhakta V; Chelala C; Caulee K; Harada T; Lemoine NR
Cancer Res; 2007 Jul; 67(14):6786-95. PubMed ID: 17638890
[TBL] [Abstract][Full Text] [Related]
11. Pyruvate kinase isoenzyme M2 is a therapeutic target of gemcitabine-resistant pancreatic cancer cells.
Kim DJ; Park YS; Kang MG; You YM; Jung Y; Koo H; Kim JA; Kim MJ; Hong SM; Lee KB; Jang JJ; Park KC; Yeom YI
Exp Cell Res; 2015 Aug; 336(1):119-29. PubMed ID: 26112218
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway.
Yao J; Qian C
Med Oncol; 2010 Sep; 27(3):1017-22. PubMed ID: 19816816
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells.
Tsai MS; Kuo YH; Chiu YF; Su YC; Lin YW
J Pharmacol Exp Ther; 2010 Dec; 335(3):830-40. PubMed ID: 20855443
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.
Dhayat SA; Mardin WA; Seggewiß J; Ströse AJ; Matuszcak C; Hummel R; Senninger N; Mees ST; Haier J
PLoS One; 2015; 10(11):e0143755. PubMed ID: 26606261
[TBL] [Abstract][Full Text] [Related]
15. DJ-1, a novel biomarker and a selected target gene for overcoming chemoresistance in pancreatic cancer.
Chen Y; Kang M; Lu W; Guo Q; Zhang B; Xie Q; Wu Y
J Cancer Res Clin Oncol; 2012 Sep; 138(9):1463-74. PubMed ID: 22526154
[TBL] [Abstract][Full Text] [Related]
16. WNT5A modulates cell cycle progression and contributes to the chemoresistance in pancreatic cancer cells.
Wei W; Sun HH; Li N; Li HY; Li X; Li Q; Shen XH
Hepatobiliary Pancreat Dis Int; 2014 Oct; 13(5):529-38. PubMed ID: 25308364
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of gemcitabine sensitivity in pancreatic cancer by co-regulation of dCK and p8 expression.
Tang K; Zhang Z; Bai Z; Ma X; Guo W; Wang Y
Oncol Rep; 2011 Apr; 25(4):963-70. PubMed ID: 21225236
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-induced autophagy promotes gemcitabine resistance in human bladder cancer cells through hypoxia-inducible factor 1α activation.
Yang X; Yin H; Zhang Y; Li X; Tong H; Zeng Y; Wang Q; He W
Int J Oncol; 2018 Jul; 53(1):215-224. PubMed ID: 29693166
[TBL] [Abstract][Full Text] [Related]
19. p8 is a new target of gemcitabine in pancreatic cancer cells.
Giroux V; Malicet C; Barthet M; Gironella M; Archange C; Dagorn JC; Vasseur S; Iovanna JL
Clin Cancer Res; 2006 Jan; 12(1):235-41. PubMed ID: 16397047
[TBL] [Abstract][Full Text] [Related]
20. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells.
Hagmann W; Jesnowski R; Löhr JM
Neoplasia; 2010 Sep; 12(9):740-7. PubMed ID: 20824050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
